Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 0.57 |
| ▸ | PIK3R1 | P27986 | 10/20 | 0.57 |
| ▸ | MTOR | P42345 | 6/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL466342 | 0.88 | PIK3CA (0.56) | PIK3CAPIK3R1MTORSMN1; SMN2PIK3CD | |
| SCHEMBL184741 | 0.88 | PIK3CA (0.74) | PIK3CAPIK3R1MTORSMN1; SMN2PIK3CD | |
| SCHEMBL190498 | 0.88 | PIK3CA (0.56) | PIK3CAPIK3R1MTORSMN1; SMN2PIK3CD | |
| SCHEMBL7898875 | 0.88 | PIK3CA (0.56) | PIK3CAPIK3R1MTORSMN1; SMN2PIK3CD | |
| SCHEMBL13871747 | 0.88 | PIK3CA (0.56) | PIK3CAPIK3R1MTORSMN1; SMN2PIK3CD | |
| SCHEMBL1088049 | 0.87 | PIK3CA (0.58) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL1181208 | 0.86 | PIK3CA (0.54) | PIK3CAPIK3R1MTORSMN1; SMN2PIK3CD | |
| SCHEMBL27906320 | 0.86 | PIK3CA (0.54) | PIK3CAPIK3R1MTORSMN1; SMN2PIK3CD | |
| SCHEMBL4076548 | 0.86 | PIK3CA (0.60) | PIK3CAPIK3R1MTORSMN1; SMN2PIK3CD | |
| SCHEMBL4556196 | 0.86 | PIK3CA (0.54) | PIK3CAPIK3R1MTORSMN1; SMN2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4694893-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME Therapeutics LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024216229-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC (US) | 2024-10-17 | — | — | WO | disclosed |
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2023-08-24 | — | — | US | disclosed |
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2023-08-24 | — | — | US | disclosed |
| CN-112920199-B | Piperazinone substituent or derivative thereof, preparation method and application thereof, and pharmaceutical composition | 四川大学 | 2023-02-03 | — | — | CN | disclosed |
| CN-112920199-A | Piperazinone substituent or derivative thereof, and preparation method, application and pharmaceutical composition thereof | 四川大学 | 2021-06-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | PIK3CA 6/4885PIK3R1 25/4885MTOR 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.